Abstract
The low-profile Acandis Acclino is aself-expandable nitinol microstent for stent-assisted coiling of intracranial aneurysms. This article reports long-term clinical and angiographic outcome in amulticenter setting. In this study 98 consecutive patients (mean age 55.4 ± 13.5 years) were treated with the Acclino for 98aneurysms (28unruptured, 20recurrent, 50ruptured) at 3 German tertiary care centers within a6-year period. The technical success, complications, clinical outcome and angiographic results were retrospectively analyzed. The technical success rate was 100% with immediate complete occlusion achieved in 89.8% of the patients. Among 65patients (66.3%) available for a 6‑month follow-up, complete and near-complete occlusion rates were 92.3% and 98.5%, respectively. In 38patients (38.8%) with long-term follow-up (mean: 21months), complete and near-complete occlusion were achieved in 81.2% and 89.5%, respectively. Aneurysm recurrence between mid-term and long-term follow-up was observed in 14.3%. The retreatment rate was 11.3%. There were three thromboembolic events (3.1%), of which one resulted in ischemic stroke (1.0%). For unruptured aneurysms, the procedural and device-related morbidity rates were 2.1% and 0%, respectively. In the present study, the Acclino was associated with alow risk of thromboembolic complications and high aneurysm occlusion rates at long-term follow-up. Due to incomplete angiographic follow-up in this series, prospective studies will be necessary to confirm the results.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.